Please assess the completion status of the following clinical trial:

Trial Title: Fluoxetine Versus Fluoxetine Plus DU125530 in Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Consecutive eligible patients aged 18 to 70~* Diagnosis of unipolar major depression using DSM-IV criteria with moderate to severe symptoms (score e 18 on the Hamilton Depression Rating Scale-HDRS- of 17 items).~* There was a wash-out of 1 week of any antidepressant drug (specifically 28 days for fluoxetine) prior entering the study.~* Written informed consent was obtained from all participants.~Exclusion Criteria:~* Concurrent psychiatric disorders (DSM IV axis I, II cluster A or B)~* Failure to respond to drug treatment in current depressive episode~* Previous resistance to SSRIs or other antidepressant drug~* Suicide risk score e 3 on the HDRS.~* Participation in other drug trials within the previous month~* Presence of delusions or hallucinations~* History of substance abuse (including alcohol) in the past three months~* Pregnancy or lactation~* Organic brain disease or history of seizures~* Serious organic illnesses such as hypo or hyperthyroidism,cardiac arrhythmias, asthma, diabetes mellitus.~* Myocardial infarction in the past 6 month~* Frequent or severe allergic reactions~* Concomitant use of other psychotropic drugs (benzodiazepines were allowed), lockers or catecholamine-depleting agents~* Current structured psychotherapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Fluoxetine plus placebo (Type: PLACEBO_COMPARATOR): None
- Fluoxetine plus DU125530 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).